Insight Molecular Diagnostics/$IMDX
1D1W1MYTD1Y5YMAX
About Insight Molecular Diagnostics
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
- Ticker
- $IMDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 57
- Headquarters
- Nashville, United States
- Website
- www.imdxinc.com
IMDX Metrics
BasicAdvanced
$141M
-
-$1.46
1.82
-
Price and volume
Market cap
$141M
Beta
1.82
52-week high
$8.51
52-week low
$2.33
Average daily volume
194K
Financial strength
Current ratio
1.997
Quick ratio
1.745
Long term debt to equity
-4.296
Total debt to equity
-12.325
Interest coverage (TTM)
-377.41%
Profitability
EBITDA (TTM)
-34.543
Gross margin (TTM)
48.74%
Net profit margin (TTM)
-2,955.63%
Operating margin (TTM)
-2,214.73%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-57.82%
Return on equity (TTM)
488.68%
Valuation
Price to revenue (TTM)
87.586
Price to book
-6.62
Price to tangible book (TTM)
-6.62
Price to free cash flow (TTM)
-4.718
Free cash flow yield (TTM)
-21.19%
Free cash flow per share (TTM)
-0.916
Growth
Revenue change (TTM)
-60.77%
Earnings per share change (TTM)
-48.91%
3-year revenue growth (CAGR)
14.90%
3-year earnings per share growth (CAGR)
-46.16%
10-year earnings per share growth (CAGR)
-17.42%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.